Entropy Technologies LP Grows Stock Holdings in DaVita Inc. $DVA

Entropy Technologies LP raised its position in shares of DaVita Inc. (NYSE:DVA) by 62.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 22,186 shares of the company’s stock after buying an additional 8,570 shares during the period. Entropy Technologies LP’s holdings in DaVita were worth $2,521,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Elevation Wealth Partners LLC lifted its position in shares of DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after buying an additional 165 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of DaVita during the second quarter valued at about $43,000. iSAM Funds UK Ltd purchased a new stake in shares of DaVita during the third quarter valued at about $46,000. Stance Capital LLC purchased a new stake in shares of DaVita during the third quarter valued at about $47,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of DaVita during the fourth quarter valued at about $45,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DaVita

In related news, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the transaction, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. This trade represents a 27.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.50% of the stock is owned by insiders.

DaVita Stock Down 0.2%

Shares of DaVita stock opened at $208.31 on Monday. The firm has a market capitalization of $13.37 billion, a P/E ratio of 19.32, a PEG ratio of 0.68 and a beta of 0.91. The company has a 50 day moving average price of $176.13 and a 200 day moving average price of $146.28. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $211.80.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.33 by $0.54. The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. DaVita’s revenue was up 6.0% on a year-over-year basis. During the same period last year, the firm posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, research analysts anticipate that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DVA has been the subject of several analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. TD Cowen increased their price target on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research report on Monday, May 11th. UBS Group increased their price target on shares of DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $199.17.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.